Home » Posts tagged with » BNT162
BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech

BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech

Pfizer and BioNTech announced that the BNT162b2 mRNA-based vaccine candidate has been shown to be more than 90% effective in the prevention of Covid-19 in participants of a phase 3 trial who were not previously exposed to the SARS-CoV-2 infection. The data is based on the first interim efficacy analysis from the phase 3 clinical […]

November 10, 2020No CommentRead More

BioNTech to acquire Novartis’ Marburg manufacturing plant to expand production of COVID-19 vaccine candidates

September 18, 2020 No Comment
BioNTech to acquire Novartis’ Marburg manufacturing plant to expand production of COVID-19 vaccine candidates

Biopharmaceutical New Technologies (BioNTech) has agreed to acquire a GMP certified manufacturing facility in Marburg, Germany from Novartis to expand the production capacity of its BNT162 COVID-19 vaccine candidates. The financial terms of the deal were not revealed by the parties. BioNTech said that the production capacity of its five mRNA COVID-19 vaccine candidates under […]

Continue reading …